NeoGenomics Reports First Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Neogenomics (NEO) PT Lowered to $21 at BTIG
May 2, 2024 5:24 AM EDTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $21.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "In this note, we update our NEO model following the company's Q1 call. NEO delivered a good 4% beat on the top line, delivered another quarter of positive Adj. EBITDA, and reiterated... More



